Important Decisions from the Board of Directors
Orion Corporation recently held an organizing meeting for its Board of Directors, following the election results from the Annual General Meeting. During this pivotal meeting, the board members charted a strategic path forward, electing Hilpi Rautelin as the Vice Chairman of the Board.
Committee Composition for Enhanced Governance
The Board of Directors took significant steps in electing members to various key committees that will oversee essential areas of governance within the organization. The following committee compositions were decided:
Personnel and Remuneration Committee
This committee is tasked with overseeing aspects related to personnel and remuneration strategies within the company. The members elected are as follows:
- Veli-Matti Mattila, Chairman
- Kari Jussi Aho
- Maziar Mike Doustdar
- Hilpi Rautelin
Audit Committee
The Audit Committee plays a crucial role in ensuring the integrity of the financial reports and effective risk management practices. The members include:
- Ari Lehtoranta, Chairman
- Eija Ronkainen
- Henrik Stenqvist
- Karen Lykke Sørensen
Research and Development Committee
This committee will focus on Orion's commitment to innovation in pharmaceuticals. The committee composition is as follows:
- Hilpi Rautelin, Chairman
- Kari Jussi Aho
- Eija Ronkainen
- Karen Lykke Sørensen
Commitment to Independence and Integrity
It's noteworthy that all newly elected board members have been assessed for independence from not only the company but also from significant shareholders. This assessment ensures that the board operates without conflicts of interest, promoting transparency and integrity in all decisions made.
Further Committees Announced
In tandem with the above committees, Orion Corporation also announced the formation of a Nomination Committee. This committee's election was previously disclosed, ensuring the governance structure remains aligned with the corporation's overarching objectives.
Contact Information for Stakeholders
If stakeholders have any inquiries regarding the Board's resolutions or other company matters, they can reach out to Olli Huotari, the EVP of Corporate Functions. He can be contacted directly at +358 50 966 3054.
Orion Corporation Overview
Orion Corporation is a prominent player in the Nordic pharmaceutical industry, having dedicated over a century to enhancing health and well-being. Orion specializes in the development and manufacture of both human and veterinary pharmaceuticals and active pharmaceutical ingredients. With a diverse portfolio that includes proprietary medications and consumer health products, Orion focuses primarily on oncology and pain management in its research and development efforts.
Orion's proprietary drugs are utilized for treating various conditions, including cancer, neurological disorders, and respiratory problems. As of 2024, Orion reported net sales of EUR 1,542 million and employed around 3,700 highly skilled professionals committed to improving health outcomes worldwide. Additionally, Orion's A and B shares are publicly traded on Nasdaq Helsinki under the ticker symbol Helsinki:ORNBV.
Frequently Asked Questions
What is the primary focus of Orion Corporation's R&D?
Orion Corporation’s R&D primarily targets oncology and pain management.
Who is the newly elected Vice Chairman of the Board?
Hilpi Rautelin has been elected as the Vice Chairman of the Board of Directors.
How many members are in the Personnel and Remuneration Committee?
The Personnel and Remuneration Committee consists of four members.
What is the role of the Audit Committee?
The Audit Committee is responsible for ensuring the integrity of financial reporting and effective risk management.
How can stakeholders reach out for inquiries?
Stakeholders can contact Olli Huotari at +358 50 966 3054 for any inquiries regarding the company matters.
